Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.7K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.7K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

8.2K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.2K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

734
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
734
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

14.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.4K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.7K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of allogeneic stem cell transplantation in peripheral T-cell lymphoma.

Bone marrow transplantation·2026
Same author

Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.

EClinicalMedicine·2026
Same author

Chronic graft-versus-host disease.

Nature reviews. Disease primers·2026
Same author

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Bone marrow transplantation·2026
Same author

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Bone marrow transplantation·2026
Same author

The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Dec 25, 2025

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

413

Acute lymphoblastic leukaemia.

Florent Malard1, Mohamad Mohty1

  • 1Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France; Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France.

Lancet (London, England)
|April 6, 2020
PubMed
Summary
This summary is machine-generated.

Acute lymphoblastic leukaemia (ALL) affects children and adults, with genetic changes impacting prognosis. Advances in risk stratification and immunotherapy offer hope for better treatment outcomes.

More Related Videos

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.2K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

476

Related Experiment Videos

Last Updated: Dec 25, 2025

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

413
Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.2K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

476

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Acute lymphoblastic leukaemia (ALL) is a common cancer in children and adults, characterized by genetic alterations in lymphoid precursor cells.
  • While predisposing factors are rare, chromosomal abnormalities and genetic alterations are key prognostic indicators in ALL.
  • Current treatments improve outcomes for younger patients, but older adults and those with relapsed or refractory disease face poor prognoses.

Purpose of the Study:

  • To summarize the current understanding of acute lymphoblastic leukaemia (ALL) pathogenesis, prognosis, and treatment.
  • To highlight the impact of genetic factors and risk stratification on ALL outcomes.
  • To discuss emerging immunotherapeutic strategies for ALL treatment.

Main Methods:

  • Review of existing literature on acute lymphoblastic leukaemia (ALL) epidemiology, genetics, and treatment outcomes.
  • Analysis of prognostic factors, including chromosomal abnormalities and genetic alterations.
  • Examination of current and novel therapeutic approaches, including chemotherapy and immunotherapy.

Main Results:

  • ALL incidence peaks between 1-4 years, with genetic alterations being crucial for cell differentiation and proliferation.
  • Risk stratification and intensified chemotherapy have improved outcomes, especially in pediatric and young adult ALL.
  • Outcomes for older adults and patients with relapsed/refractory ALL remain challenging.

Conclusions:

  • Genetic alterations are central to ALL pathogenesis and prognosis, guiding risk stratification and treatment intensity.
  • While chemotherapy has improved outcomes, novel immunotherapies like CAR T-cells and monoclonal antibodies represent the future of ALL treatment.
  • Further research into immunotherapeutic strategies is crucial to improve survival rates for all ALL patient groups, particularly older adults and those with refractory disease.